ReviewAdvanced pharmaceutical bulletin2022
Microfluidics - The State-of-the-Art Technology for Pharmaceutical Application.
Review in Advanced pharmaceutical bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances in Polymer Science and Fabrication Processes for Enhanced Microfluidic Applications: An Overview.Micromachines · 2024Review
- In-depth Exploration of the Basics of Microfluidic Cell Deformability to Unveil its Applications in the Modern Era.Current pharmaceutical design · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microfluidics (MF) is the science dealing with the behavior, precise control, and manipulation of fluids as well as particles on the scale of tens to hundreds of micrometers. It is also utilized for chemical and biological applications, usually called micro-total analysis systems (µTAS) or lab-on-a-chip (LOC). MF is a fascinating and capable technology with various superior benefits compared to conventional macro-scale platforms, such as the lesser requirement of sample and reagent volumes, higher sensitivity, low cost, portability, faster processing of samples and potential to be automated and highly integrated to reduce human errors. The concept of transformation of meso to nanoliters using MF technology has shown its potential in the healthcare system for early diagnosis, and personalized medicine. The integrated multifunctional system with parallelization provides a better and faster process control. Minimization of the consumption of fluid makes the technology safer in every aspect of the development process, analysis, and storage. The impressive improvement in patient care and monitoring has led to the commercial motivation of the pharmaceutical industry to develop new drugs and modify existing products with better efficacy and safety in a cost-effective manner using MF technologies. Hence, the present review briefs on the applications of MF technology in the key issues of the drug discovery process, overcoming the limitations of development of analytical procedures and prosperous pharmaceutical manufacturing for novel controlled and targeted release dosage forms to fabricate quality products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.